ARGENX SE ARGX

Latest FY: 2025 Healthcare Biotechnology
Market Price $851.51
Market Cap $53.03B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑31.4% YoY
$2.87B
3-Yr CAGR: 559.2%
Net Income ↑55.1% YoY
$1.29B
Net Margin: 45.0%
Free Cash Flow ↓-273.7% YoY
-$5.26M
FCF Yield: -0.01%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
17.6%
ROA: 14.9%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ARGX)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (+147.5%) is identical to Gross Profit YoY (+147.5%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
  • FY 2018: Revenue YoY (-41.0%) is identical to Gross Profit YoY (-41.0%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
  • FY 2019: Revenue YoY (+224.8%) is identical to Gross Profit YoY (+224.8%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
  • FY 2020: Revenue YoY (-47.8%) is identical to Gross Profit YoY (-47.8%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
  • FY 2021: Revenue YoY (+1265.2%) is identical to Gross Profit YoY (+1265.2%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
  • FY 2023: Revenue YoY (+254.4%) is identical to Gross Profit YoY (+254.4%). Verify the underlying Revenue and Gross Profit values for FY 2023 and FY 2022.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $14.7M $12.4M $-21.4M
FY 2017 $36.4M +147.5% $30.7M $-28.1M -31.4%
FY 2018 $21.5M -41.0% $18.1M $-66.6M -137.4% $-0.6M $-1.2M
FY 2019 $69.8M +224.8% $58.8M $-163.0M -144.5% $0.1M $-1.5M -24.7%
FY 2020 $36.4M -47.8% $30.7M $-528.9M -224.6% $0.3M $-0.6M +59.5%
FY 2021 $497.3M +1,265.2% $419.2M $-408.3M +22.8% $0.7M $-2.9M -389.8%
FY 2022 $10.0M -98.0% $10.0M $-709.6M -73.8% $0.9M $0.0M +100.5%
FY 2023 $35.5M +254.4% $35.5M $-295.1M +58.4% $0.2M $-0.6M -4,392.9%
FY 2024 $2,185.9M +6,051.7% $1,958.6M $833.0M +382.3% $0.4M $-1.4M -134.4%
FY 2025 $2,871.5M +31.4% $2,420.9M $1,292.0M +55.1% $0.9M $-5.3M -273.7%
$

Valuation

Market Price $851.51
Market Cap $53.03B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio 7.20
FCF Yield -0.01%
Dividend Yield N/A
Shares Outstanding 61,883,306
%

Profitability & Margins

Gross Margin 84.31%
Operating Margin 36.70%
Net Margin 44.99%
Return on Equity (ROE) 17.64%
Return on Assets (ROA) 14.88%
Asset Turnover 0.33x
Revenue 3-Yr CAGR 559.17%
🛡️

Financial Health & Liquidity

Current Ratio 163.45
Cash Ratio 82.71
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents $3.49B
Total Debt N/A
Book Value / Share $118.34
💧

Cash Flow Efficiency

Operating Cash Flow $900.00K
Capital Expenditures (CapEx) $6.17M
Free Cash Flow -$5.26M
OCF / Revenue 0.03%
FCF / Revenue -0.18%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share $118.34
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $8.68B
Total Liabilities $1.36B
Stockholders' Equity $7.32B
Current Assets $6.90B
Current Liabilities $42.21M